rs121912833
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM5PP2PP3_StrongPP5_Very_Strong
The NM_000094.4(COL7A1):c.4039G>T(p.Gly1347Trp) variant causes a missense change. The variant allele was found at a frequency of 0.00000682 in 1,613,896 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1347R) has been classified as Pathogenic.
Frequency
Consequence
NM_000094.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 15 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL7A1 | NM_000094.4 | c.4039G>T | p.Gly1347Trp | missense_variant | 35/119 | ENST00000681320.1 | NP_000085.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL7A1 | ENST00000681320.1 | c.4039G>T | p.Gly1347Trp | missense_variant | 35/119 | NM_000094.4 | ENSP00000506558 | P1 | ||
COL7A1 | ENST00000328333.12 | c.4039G>T | p.Gly1347Trp | missense_variant | 34/118 | 1 | ENSP00000332371 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152188Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251024Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135804
GnomAD4 exome AF: 0.00000684 AC: 10AN: 1461708Hom.: 1 Cov.: 35 AF XY: 0.00000963 AC XY: 7AN XY: 727158
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152188Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74350
ClinVar
Submissions by phenotype
Recessive dystrophic epidermolysis bullosa Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Mar 30, 2023 | This sequence change is predicted to replace glycine with tryptophan at codon 1347 of the COL7A1 protein (p.(Gly1347Trp)). The glycine residue is evolutionarily conserved (invariant in 100 vertebrates, UCSC), and is located in a Gly-X-Y repeat in the collagen triple helical region (PM1). There is a large physicochemical difference between glycine and tryptophan. The variant is present in a single individual in a large population cohort (PM2; 1/251,024 alleles in gnomAD v2.1). The variant has been identified with a second pathogenic allele in at least four cases with recessive dystrophic epidermolysis bullosa (PM3_Strong; PMID: 18565177, 21113014, 21382783, 26707537). Multiple lines of computational evidence predict a deleterious effect for the missense substitution (PP3; 6/6 algorithms). A similar pathogenic missense change involving the glycine (p.Gly1347Arg) at this position has been seen before (PM5; ClinVar). Based on the classification scheme RMH ACMG Guidelines v1.2.1, this variant is classified as PATHOGENIC. Following criteria are met: PM3_Strong, PM1, PM2, PM5, PP3. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 09, 2024 | Variant summary: COL7A1 c.4039G>T (p.Gly1347Trp) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251024 control chromosomes. c.4039G>T has been reported in the literature in individuals affected with Dystrophic Epidermolysis Bullosa, Recessive (Kern_2006, Schumann_2008, vandenAkker_2011, Kopeckova_2016). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 16484981, 18565177, 21113014, 34826142, 21382783, 26707537). ClinVar contains an entry for this variant (Variation ID: 937822). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 05, 2022 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the triple helix domain of COL7A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236), and variants at these glycine residues in COL7A1 are more frequently observed in individuals with disease than in the general population (PMID: 22058051). However, the clinical significance of this observation remains uncertain since only a limited number of affected individuals have been described to date. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL7A1 protein function. ClinVar contains an entry for this variant (Variation ID: 937822). This missense change has been observed in individuals with autosomal recessive dystrophic epidermolysis bullosa (PMID: 16484981, 18565177, 21113014). This variant is present in population databases (rs121912833, gnomAD 0.007%). This sequence change replaces glycine, which is neutral and non-polar, with tryptophan, which is neutral and slightly polar, at codon 1347 of the COL7A1 protein (p.Gly1347Trp). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at